Sign in
CompletedNo phase

Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting

Key facts

Who runs it
Azienda Ospedaliero, Universitaria Pisana
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
31 people enrolled
Started
1 Oct 2023
Ended
30 Jun 2025
Type of study
Observational
Treatments tested
  • Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting
Record updated
20 August 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Signed informed consent form
  • Diagnosis of chronic insomnia according to DSM-5 criteria, defined as:; Dissatisfaction with sleep quantity or quality, associated with one or more of the following:; Difficulty initiating sleep; Difficulty maintaining sleep (frequent awakenings or trouble returning to sleep); Early morning awakenings with inability to return to sleep; The sleep disturbance causes clinically significant distress or impairment in social, occupational, educational, academic, or other important areas of functioning; Sleep difficulties occur despite adequate opportunity and circumstances for sleep; The insomnia is not better explained by or occurring exclusively during other sleep-wake disorders (e.g., narcolepsy, parasomnias, circadian rhythm sleep-wake disorders, breathing-related sleep disorders); The insomnia is not attributable to the physiological effects of a substance (e.g., drug abuse or medication)
  • No contraindications to daridorexant use according to the European Medicines Agency (EMA)

Who cannot take part

  • Pregnancy
  • Breastfeeding
  • Withdrawal of informed consent at any time

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objectives of this study is to evaluate the real-world effectiveness of daridorexant 50 mg in improving both subjective (self-report) and objective (actigraphic) sleep parameters in patients with chronic insomnia.

Read full original descriptionShow less

The secondary aims of this study are:

* To compare the effectiveness of daridorexant 50 mg with other guideline-recommended therapies for chronic insomnia in improving sleep parameters and sleep health. * To identify clinical and demographic predictors of response to daridorexant 50 mg, such as age, sex, BMI, duration of insomnia, and treatment regimen (monotherapy vs. add-on). * To monitor changes over time in the symptoms related to comorbid sleep disorders (e.g., OSA, RLS, circadian rhythm disorders) in patients treated with daridorexant 50 mg.

Treatments tested

  • Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia Using Subjective and Actigraphic Sleep Measures in a Real-World Setting
Record updated
20 August 2025